Effect of Prophylactic Human Papillomavirus (HPV) Vaccination on Oral HPV Infections Among Young Adults in the United States
Top Cited Papers
- 20 January 2018
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 36 (3), 262-267
- https://doi.org/10.1200/jco.2017.75.0141
Abstract
The incidence of human papilloma virus (HPV)–positive oropharyngeal cancers has risen rapidly in recent decades among men in the United States. We investigated the US population–level effect of prophylactic HPV vaccination on the burden of oral HPV infection, the principal cause of HPV-positive oropharyngeal cancers. We conducted a cross-sectional study of men and women 18 to 33 years of age (N = 2,627) within the National Health and Nutrition Examination Survey 2011 to 2014, a representative sample of the US population. Oral HPV infection with vaccine types 16, 18, 6, or 11 was compared by HPV vaccination status, as measured by self-reported receipt of at least one dose of the HPV vaccine. Analyses accounted for the complex sampling design and were adjusted for age, sex, and race. Statistical significance was assessed using a quasi-score test. Between 2011 and 2014, 18.3% of the US population 18 to 33 years of age reported receipt of at least one dose of the HPV vaccine before the age of 26 years (29.2% in women and 6.9% in men; P < .001). The prevalence of oral HPV16/18/6/11 infections was significantly reduced in vaccinated versus unvaccinated individuals (0.11% v 1.61%; Padj = .008), corresponding to an estimated 88.2% (95% CI, 5.7% to 98.5%) reduction in prevalence after model adjustment for age, sex, and race. Notably, the prevalence of oral HPV16/18/6/11 infections was significantly reduced in vaccinated versus unvaccinated men (0.0% v 2.13%; Padj = .007). Accounting for vaccine uptake, the population-level effect of HPV vaccination on the burden of oral HPV16/18/6/11 infections was 17.0% overall, 25.0% in women, and 6.9% in men. HPV vaccination was associated with reduction in vaccine-type oral HPV prevalence among young US adults. However, because of low vaccine uptake, the population-level effect was modest overall and particularly low in men.This publication has 17 references indexed in Scilit:
- Cancer statistics, 2016CA: A Cancer Journal for Clinicians, 2016
- Epidemiology of Human Papillomavirus–Positive Head and Neck Squamous Cell CarcinomaJournal of Clinical Oncology, 2015
- Propensity Score Analysis with Survey Weighted DataJournal of Causal Inference, 2015
- Primary endpoints for future prophylactic human papillomavirus vaccine trials: towards infection and immunobridgingThe Lancet Oncology, 2015
- US Assessment of HPV Types in Cancers: Implications for Current and 9-Valent HPV VaccinesJNCI Journal of the National Cancer Institute, 2015
- Reduction in Human Papillomavirus (HPV) Prevalence Among Young Women Following HPV Vaccine Introduction in the United States, National Health and Nutrition Examination Surveys, 2003–2010The Journal of Infectious Diseases, 2013
- Reduced Prevalence of Oral Human Papillomavirus (HPV) 4 Years after Bivalent HPV Vaccination in a Randomized Clinical Trial in Costa RicaPLOS ONE, 2013
- Prevalence of Oral HPV Infection in the United States, 2009-2010JAMA, 2012
- Human Papillomavirus and Rising Oropharyngeal Cancer Incidence in the United StatesJournal of Clinical Oncology, 2011
- Testing logistic regression coefficients with clustered data and few positive outcomesStatistics in Medicine, 2008